Compare TBPH & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | ASM |
|---|---|---|
| Founded | 2013 | 1968 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 798.8M |
| IPO Year | N/A | N/A |
| Metric | TBPH | ASM |
|---|---|---|
| Price | $18.73 | $5.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $27.80 | $5.27 |
| AVG Volume (30 Days) | 601.0K | ★ 4.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 476.57 |
| EPS | ★ 0.58 | 0.14 |
| Revenue | $80,327,000.00 | ★ $86,065,000.00 |
| Revenue This Year | $70.78 | $38.58 |
| Revenue Next Year | N/A | $39.81 |
| P/E Ratio | ★ $32.19 | $41.24 |
| Revenue Growth | 27.12 | ★ 58.42 |
| 52 Week Low | $7.90 | $0.85 |
| 52 Week High | $20.33 | $6.67 |
| Indicator | TBPH | ASM |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 62.30 |
| Support Level | $18.39 | $5.19 |
| Resistance Level | $20.32 | $5.72 |
| Average True Range (ATR) | 0.87 | 0.31 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 53.71 | 81.43 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.